Psychoeducation Based on Acceptance and Commitment Therapy

May 7, 2025 updated by: Fatmanur ÖZCAN MİRCALI, Muğla Sıtkı Koçman University

Investigation of the Effect of Acceptance and Commitment Therapy-Based Psychoeducation on Rumination and Self-Compassion in Patients Diagnosed With Panic Disorder: Randomized Controlled Study

The aim of this study is to manage individual psychoeducation in acceptance and commitment therapy for problems with panic disorder and to evaluate the effect of this program on rumination and self-resilience.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Panic disorder; palpitations, sweating, tachycardia, fear of death, depersonalization, derealization, fear of going crazy, etc. It is a psychiatric disorder with symptoms. The most commonly used psychotherapy method for panic disorder patients is cognitive behavioral therapies. Acceptance and Commitment Therapy is a psychotherapy method originating from cognitive behavioral therapy. Acceptance and Commitment Therapy helps individuals act in the direction of their values by allowing them to contact their painful experiences rather than trying to escape or try to get rid of their difficult experiences, thoughts, and feelings. Acceptance and Commitment Therapy supports psychological well-being by providing psychological flexibility in the person. Rumination is mental rumination, which is used to keep thoughts spinning in the mind repetitively after an event.Self-compassion is a concept used to mean understanding oneself despite one's mistakes. This study aims to create psychoeducation based on acceptance and commitment therapy for patients with panic disorder and to evaluate the effect of this program on rumination and self-compassion. Psychoeducation, an evidence-based practice, is very important for the nursing profession. Although nurses have a significant impact on psychoeducational practices, this role is ignored and not implemented adequately. In addition, since there is no research examining the concepts of rumination and self-compassion together in people with panic disorder, it is thought that our study will be useful in new research.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
50

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Turkey
    • Mentese
      • Mugla, Mentese, Turkey, 48000
        • Muğla Sıtkı Koçman University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients diagnosed with Panic Disorder followed in Muğla Training and
  • Research Hospital Psychiatry Polyclinics,
  • Those between the ages of 18-65 who agree to participate in the research,
  • Those who were in a euthymic mood during the interview, according to physician control,
  • Those who speak Turkish,
  • Those who are literate,
  • Those who have a computer and internet access for the program to be conducted online if deemed necessary during the research process,
  • Not having undergone such training within the last year is within the scope of the inclusion criteria.

Exclusion Criteria:

  • Having a diagnosis of a psychiatric disease in addition to panic disorder,
  • Having an attack period during the training period,
  • Individuals with cognitive (diagnosed by a physician) and physical disability (hearing, speaking, etc.) are included in the exclusion criteria from the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: psycoeducation
Psychoeducation based on acceptance and commitment therapy will be applied to the experimental group of 25 people. Pre-test, post-test and follow-up test will be applied.
Other: Acceptance and Commitment Therapy-Based Psychoeducation
Psychoeducation based on acceptance and commitment therapy will be applied to the experimental group.
Active Comparator: control
No intervention will be applied to the control group of 25 people. Pre-test, post-test and follow-up test will be applied.
Other: control group
No intervention will be applied to the control group.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Ruminative Thought Style Questionnaire
Time Frame: 7 week
The scale is a 7-point Likert type consisting of 20 items. 7 = Very good and 1 = Not at all, and participants are asked to score each item according to how much it reflects themselves. The internal consistency coefficient of the scale, Cronbach's alpha value, was found to be .907. In the item analysis, the item total score correlation was calculated and the total correlations of the items were found to be between 0.474 and 0.699.
7 week

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Self Compassion Scale
Time Frame: 7 week
The original Self-Compassion Scale consists of 6 subscales containing 26 items. The scale is a 5-point Likert type and those who answer "almost never = 1 and almost always = 5" are asked to rate how often they move. The Turkish form of the self-compassion scale, unlike the original, consists of 24 items because the scale shows a unidimensional structure and at the same time, 2 items with item-total correlations below 30 were removed from the scale. The internal consistency coefficient of the scale was calculated as .89 and the test-retest correlation was calculated as .83.
7 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Muğla Sıtkı Koçman University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 30, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 30, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 30, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 21, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 23, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 26, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 8, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 7, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • MuglaSKU-HEM-FOM-01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings